Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Inclusion Criteria: * Age greater than or equal to 18 years. * Histologically or cytologically confirmed diagnosis of MCL. * Relapsed or refractory MCL patients who have received at least one prior therapy are eligible. Patients who have previously received high-dose chemotherapy with peripheral stem cell support are eligible. * Presence of at least one lymph node evaluable or mass measurable for response. * Eastern Cooperative Oncology Group Performance Status greater than 2. * Platelets \> 75,000/μL and absolute neutrophils count (ANC) \> 1,000/μL within 14 days of study registration (unless the treating physician deems the neutropenia is related to bone marrow involvement, then an ANC of \> 750/mm 3 is allowed) * Normal renal function defined as serum creatinine less than 2. * Recovery from any previous treatment therapy. * Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test * All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program. * Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program. * Ability to understand, and willingness to sign, a written informed consent document. * Able to take aspirin (81 or 325 mg) daily as prophylactic anti-coagulation (patients intolerant to ASA may use low molecular weight heparin). * Normal organ and bone marrow function parame…